Utility of the trough plasma imatinib level monitoring at two time points in patients with the chronic myeloid leukemia-chronic phase | Zendy

Tulika Seth | Zendy; Sanjeev Sharma | Zendy; Suman Kumar | Zendy; Vijayakumar Arumugam Ramamurthy | Zendy; Pravas Mishra | Zendy; Manoranjan Mahapatra | Zendy; Sudha Sazawal | Zendy; T Velpandian | Zendy; Renu Saxena | Zendy

Open Access

Utility of the trough plasma imatinib level monitoring at two time points in patients with the chronic myeloid leukemia-chronic phase

Author(s) -

Tulika Seth,

Sanjeev Sharma,

Suman Kumar,

Vijayakumar Arumugam Ramamurthy,

Pravas Mishra,

Manoranjan Mahapatra,

Sudha Sazawal,

T Velpandian,

Renu Saxena

Publication year - 2014

Publication title -

journal of cancer research and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.475

H-Index - 39

eISSN - 0973-1482

pISSN - 1998-4138

DOI - 10.4103/0973-1482.136583

Subject(s) - imatinib , myeloid leukemia , medicine , trough level , imatinib mesylate , chronic myelogenous leukemia , oncology , leukemia , gastroenterology , pharmacology , immunology , transplantation , tacrolimus

Plasma imatinib levels vary widely in patients with the chronic myeloid leukemia-chronic phase, and studies have shown improved hematological, cytogenetic, and molecular responses in patients with the higher trough imatinib levels.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research